22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
Did you know that when a private sector employer has evidence that a union has lost support from a m...
Read More >
Most parties on a construction project know that a liquidated damage may be assessed for each day of...
Read More >
The Federal Trade Commission (“FTC”) announced its annual adjustment for notification thresholds f...
Read More >
In the changing employment environment surrounding the current outbreak of the 2019 Novel Coronaviru...
Read More >
In December 2019, U.S. lawmakers passed the SECURE (Setting Every Community Up for Retirement Enhanc...
Read More >
In HKSAR v Gammon Construction Limited (HCMA 97/2019) [2020] HKCA 752 (Date of Judgment: 7 September...
Read More >